The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings
Author:
Affiliation:
1. Department of Neurology, University Hospital, University of Lund, Sweden.
2. Merck Serono S.A. – Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
Abstract
Publisher
SAGE Publications
Subject
Neurology (clinical),Neurology
Link
http://journals.sagepub.com/doi/pdf/10.1177/1352458511403642
Reference22 articles.
1. Interferons and multiple sclerosis: is it plausible that β-IFN treatment could influence the risk of cancer among MS patients?
2. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
4. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
5. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society;Multiple Sclerosis Journal;2024-02-15
2. Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population;Advances in Clinical Neuroscience & Rehabilitation;2024
3. Cancer risk, disease-modifying therapy, and age in multiple sclerosis: A retrospective population-based cohort study;Multiple Sclerosis and Related Disorders;2023-12
4. Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case–control study within the French nationwide claims database;Pharmacoepidemiology and Drug Safety;2023-08-09
5. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis;Neurotherapeutics;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3